1 results match your criteria: "Hospital Universitario Ramón y Cajalgrid.411347.4-IRYCIS[Affiliation]"
Imipenem-Relebactam Susceptibility in Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies).
Microbiol Spectr
October 2022
Servicio de Microbiología, Hospital Universitario Ramón y Cajalgrid.411347.4-IRYCIS, Madrid, Spain.
Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the activity of imipenem-relebactam and comparators against clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (ICUs) (SUPERIOR, 2016-2017; STEP, 2017-2018). Overall, 747 isolates (378 Escherichia coli, 252 Klebsiella spp.
View Article and Find Full Text PDF